By
Pfizer Chairman and CEO Albert Bourla said Wednesday “preliminary research” shows people may need a fourth COVID shot, as Fauci, CDC signal definition of fully vaccinated will change.
Pfizer and BioNTech released results from their initial lab study showing a third dose was protective against the new variant, but the initial two-dose series dropped significantly in its ability to protect against the new strain.
The two-dose series may still offer protection against severe sickness from Omicron, the companies claimed.
“Three doses against Omicron are almost equivalent to the two doses’ effectiveness against … the original variant,” Bourla said in an interview with TODAY. “If we need a new vaccine … we will be able to have a very good one.”
Bourla said the preliminary study was based on a synthetic, lab-created copy of the variant, and more data is needed from tests using the actual virus. Real-world results will be more accurate and are expected in the next two weeks, he said.
“When we see real-world data, we will determine if the Omicron is well covered by the third dose and for how long,” Bourla told CNBC’s “Squawk Box.” “And the second point, I think we will need a fourth dose.”
[…]
